This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases.
This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical
credit:
company partners.
Strong applications will include scientific evidence that modulation of an Assets target should have a positive impact on the disease/condition.
An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-00 3. X02 pre-applications will be evaluated by outside experts.
Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA.
The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities.
If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.